Subscribe to the BioNews newsletter for free

Advanced Search

Search for

Like the Progress Educational Trust on Facebook


Blood test can tell when prostate cancer drugs stop working

22 September 2014

By James Brooks

Appeared in BioNews 772

A study where the tumour DNA of 16 prostate cancer patients was frequently checked suggests that, in some patients, commonly used anti-cancer drugs may actually boost tumour growth after a while.

The research relied on analysis of tumour DNA circulating in patients' blood, rather than repeated biopsies. The findings need to be checked in larger studies but the researchers say that monitoring circulating tumour DNA could eventually help doctors check when prostate cancer treatments are no longer working and change the treatment course accordingly.

Professor Paul Workman, interim chief executive at The Institute of Cancer Research, UK, which collaborated in the study, said: 'This important discovery reveals how some cancer treatments can actually favour the survival of the nastiest cancer cells, and sets out the rationale for repeated monitoring of patients using blood tests, in order to track and intervene in the evolution of their cancers'.

One of the key findings was that, after an initial period of effectiveness, drugs called gluticocorticoids appeared to activate dangerous mutations in the tumour which contributed to the progression of the disease. Gluticocorticoids are steroidal drugs frequently prescribed to prostate cancer patients alongside hormone therapy.

Speaking to the Daily Mail, study leader Dr Gerhardt Attard said: 'Glucocorticoids are initially effective, they are great treatments which we have been using for more than a decade now. They make people feel better and their tumours shrink'.

'But in time - it could be a couple of years or less, depending on the patient - the cancer manages to adapt and start growing again. In one in five people the treatment might start driving the disease, activating harmful mutations'.

The researchers stressed that the study was an early piece of research and needed to be confirmed in more patients. Dr Matthew Hobbs, deputy director of research at Prostate Cancer UK, which provided the majority of funding for the study, said: 'Anyone currently taking medication for advanced prostate cancer should not stop doing so as a result of these findings, but should speak to their clinician if they have any concerns'.

The study also suggested that measuring levels of circulating tumour DNA might give a reliable indication of the emergence of treatment-resistant prostate cancer. Currently doctors rely on repeated biopsies, which are more invasive and, the researchers say, more expensive.

In the UK, prostate cancer is the commonest cancer in men with more than 40,000 new cases diagnosed each year.

The study is published in Science Translational Medicine.

Institute of Cancer Research (press release) | 17 September 2014
The Telegraph | 17 September 2014
MailOnline | 17 September 2014
Independent | 18 September 2014
Science Translational Medicine | 17 September 2014
Cancer Research UK (press release) | 17 September 2014


26 June 2017 - by Charlotte Spicer 
A new three-in-one blood test could progress personalised treatment for patients with prostate cancer...
09 November 2015 - by Kirsty Oswald 
Researchers have identified the genetic mutations that drive resistance to the hormone therapy abiraterone in patients with advanced prostate cancer...
01 September 2015 - by Hannah Somers 
Scientists have developed a blood test that can predict several months in advance which breast cancer patients will relapse.
03 August 2015 - by Kirsty Oswald 
Researchers have found that prostate cancer can be divided into five subgroups with distinct genetic fingerprints...
26 May 2015 - by Dr Julia Hill 
Scientists have announced a comprehensive genetic map of prostate cancer, which they say could lead to new treatments for the advanced stage of the disease...

15 September 2014 - by Dr Anna Cauldwell 
Twenty-three genetic variants associated with increased risk of prostate cancer have been identified in a new study, bringing the total number of susceptibility variants for the disease to 100...
14 April 2014 - by Simon Hazelwood-Smith 
A genetic test has been developed to predict the likelihood of prostate cancer returning after treatment. The test looks for 'genetic signatures' often found in recurring cancers...
24 February 2014 - by Julianna Photopoulos 
Genetic screening could help identify men who are most likely to develop an aggressive form of prostate cancer, a study shows...
15 July 2013 - by Julianna Photopoulos 
Scientists have developed a 'barcode' blood test that reads genetic changes to pick out the most aggressive prostate cancers...

Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions

- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation